

What Can We Learn from the Evolution of Protein-Ligand Interactions to Aid the Design of New Therapeutics?

Alicia P. Higuieruelo^{1*}, Adrian Schreyer¹, G. Richard J. Bickerton^{1‡}, Tom L. Blundell¹, Will R. Pitt^{1,2}

¹ Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, ² UCB Pharma, Slough, United Kingdom

Overview

2

- Introduction
- Protein-protein interactions as drug targets
 - ▣ TIMBAL db
- Molecular recognition in structural databases
 - ▣ Comparison of different molecular subsets
 - ▣ Polarity of interactions
 - ▣ Interaction profile vs molecular properties
- Conclusions

Introduction

3

- The struggle of drug discovery to deliver drugs into the market is a many fold problem
 - ▣ From target selection to FDA regulations
- Focusing in the profile of drug candidates
 - ▣ Small molecules are far too lipophilic (*)
 - ▣ Correlation of logP with compound promiscuity (**)
 - ▣ Current opinion in DD is to try to keep logP low

* Molecular obesity, Hann 2011, MedChemComm 2:349

** Leeson & Springthorpe 2007, NatRevDD 6:881

** Gleeson et al 2011, NatRevDD 10:197


Introduction

4

- The struggle of drug discovery to deliver drugs into the market is a many fold problem
 - From target selection to FDA regulations
- Focusing in the profile of drug candidates
 - Small molecules are far too lipophilic
 - Correlation of logP with compound promiscuity
 - Current opinion in DD is to try to keep logP low
- Pursuing other targets
 - Protein-protein interactions

TIMBAL database – PPI modulators

5



The screenshot shows the TIMBAL database website. At the top, there is a navigation bar with links for 'TIMBAL', 'About', 'Download', 'Contact', and 'Thanks!'. The main content area features the title 'TIMBAL' in large, bold, black letters. Below the title, it says 'Welcome to the TIMBAL database'. Underneath, there is a section titled 'Select a target from the list' with a sub-note: 'SM for the targets marked with *** are stabilisers of PPI'. A search input field contains the text '*** 14-3-3' and a blue button labeled 'Retrieve data' with a magnifying glass icon. To the right of the text is a 3D molecular model of a protein structure, showing a grey surface representation and a pink ribbon representation. At the bottom of the page, there is a light blue footer bar with the text 'Last update 02-MAY-2014 using ChEMBL_18'. Below this, on the left, is the University of Cambridge logo and name. On the right, there is a small 'OPEN KNOWLEDGE' logo followed by the text 'TIMBAL holds small molecules modulating protein-protein interactions'.

TIMBAL database - analyses

6

- In comparison with drugs and screening sets, small molecules disrupting protein-protein interfaces are
 - ▣ Bigger
 - ▣ More lipophilic
 - ▣ Less hydrogen bonding
- In correlation with the type of contacts these molecules made

That's interesting

7

- Large, sticky, lipophilic molecules with few HB features are likely to be:
 - ▣ Promiscuous
 - ▣ Difficult to develop into a drug

Natural questions:

- Is this a requirement of the multi-protein interfaces?
- Or a short cut in Medicinal Chemistry?

Can we study molecular recognition?

From our structural databases

CREDO	protein – small molecules
	protein – small peptides
PICCOLO	protein – protein

Contact definitions

9

- Hydrogen-bonds calculation are not trivial
 - ▣ Proteins have a finite number of atom types
 - ▣ Small molecules are too diverse
- Homogenous definition of contacts for cross-comparison
 - ▣ Simple distance cut-off and atom type

Polar and **apolar** contacts



Can we study molecular recognition?

trends of

atomic interactions (polar vs apolar)

for


meaningful subsets of molecules

Subsets from CREDO and PICCOLO


11

	Subset	Annotation source
Small molecules	Synthetic small molecules	Chemical filters
	Approved and oral drugs	DrugBank, ChEMBL
	Natural Molecules	KEGG, HMDB, ChEMBL
	Small Peptides	CREDO
	PPI Inhibitors	TIMBAL
Proteins	Obligate / transient dimers	Mintseris, NOXClass
	Quaternary interfaces	PICCOLO, PISA

Scissors plots




12




- Plot polar and apolar contacts versus sum of contacts
- Openness of the trend lines gives the ratio of polar contacts versus apolar


Nature does more polar




13






open




closed







medium



Nature does more polar



14



How can we explain this?

Atomic composition

heteroatoms ratio

Flexibility

rotatable bonds ratio

Flexibility small molecules

16


- Count of rotatable bonds and heteroatoms

	Profile	RotBonds / N_at	Hetatms / N_at
Synthetic SM	Apolar	Rigid	Low
Natural molecules	Polar	Rigid	High
Small Peptides	Polar	Flexible	Low

- Natural molecules have higher content in heteroatoms placed in the right conformation
- Peptides compensate the lower heteroatom content with more flexibility


Matched and unmatched atoms


From this molecular composition, how many atoms are successfully interacting with the protein target?



Matched and unmatched atoms


From this molecular composition, how many atoms are successfully interacting with the protein target?






Matched atoms

19




- Small molecules more contact efficient than proteins
- Mainly small molecules are wrapped by the protein



Unmatched atoms


20



- Synthetic molecules have higher proportion of unmatched polar atoms
- Drugs **are not** making the most of their polar composition

Making the most of your atomic composition

21



Molecular properties for Drugs


22

- Natural molecules:
 - ▣ Are synthesised in-situ
 - ▣ Do not need to be absorbed and distributed
- Maybe what it takes to be a drug constrains the polar specific contacts that a drug-like molecule can make?

Molecular properties for Drugs

23

- Natural molecules:
 - ▣ Are synthesised in-situ
 - ▣ Do not need to be absorbed and distributed
- Maybe what it takes to be a drug constrains the polar specific contacts that a drug-like molecule can make?




Properties vs interaction profile

For synthetic small molecules

Synthetic small molecules: properties and interaction profile

25




Synthetic small molecules bound to different SCOP fam

- Trends depending on their targets
- **No correlation** between lipophilicity or MW and polar interactions
- ex:
 - logP 4 presents a range of 4-37% polar contacts

Synthetic small molecules: properties and interaction profile


26



Synthetic small molecules bound to different SCOP fam

□ But

- ▣ higher polar ratio happens for smaller molecules (fragments)



Going back to the initial question...

27


- Large, sticky, lipophilic molecules with few HB features are likely to be:
 - Promiscuous
 - Difficult to develop into a drug

Natural questions:

- Is this a requirement of the multi-protein interfaces?
- Or a short cut in Medicinal Chemistry?

Protein-protein inhibitors

28



Conclusions I

- Natural complexes typically engage more polar interactions than synthetic molecules
- Synthetic small molecules have higher proportion of unmatched heteroatoms
- For synthetic small molecules in general, but for PPI in particular we conclude that early efforts should be invested to increase polar contacts
 - ▣ better resemble the interaction patterns of natural molecules
 - ▣ minimise promiscuity and poor ADMET profile

Conclusions II

30

- Synthetic small molecules show no correlation between logP and ratio of polar contacts
 - ▣ suggesting the improvement of specific interactions should not change drastically the molecular properties
- Ratio of polar contacts is higher for smaller molecules
 - ▣ Fragments anchor with higher proportion of specific contacts
- Current viewpoints in the field advocate to improve affinity of fragments *before* adding MW to maximise interactions with the original hot spot

Thank you!

- Tom Blundell
- Richard Bickerton
- Graham Eliff
- Sungsam Gong
- Colin Groom
- Marko Hyvönen
- Harry Jubb
- Semin Lee
- Rinaldo Montalvão
- Bernardo Ochoa
- Tjelvar Olsson
- Will Pitt
- Adrian Schreyer
- Jawon Song
- Duangrudee Tanramluk
- Nikolay Todorov

